{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T16:13:36Z","timestamp":1744215216569},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The number of patients diagnosed with hepatitis C virus (HCV) is markedly higher than the number initiating treatment indicating gaps in the care cascade, likely centred around reaching at\u2010risk populations. Understanding changing characteristics of patients with HCV allows for targeted programs that increase linkage to care. We investigated changes in demographic and clinical characteristics of patients registered in the German Hepatitis C\u2010Registry (DHC\u2010R) from 1\u00a0January 2014 to 31 December 2019. The DHC\u2010R is an ongoing, noninterventional, multicentre, prospective, observational cohort registry including 327 German centres. Patient characteristics were analysed over time in 7 phases for all patients completing a screening visit. Overall, 14,357 patients were enrolled. The percentage of treatment\u2010na\u00efve\/non\u2010cirrhotic patients increased from 34.4% in phase 1 (1\u00a0January\u201331 December 2014) to 68.2% in phase 7 (1 August\u201331 December 2019). The proportion of migrants, alcohol users, people who inject drugs, and those receiving opiate substitution therapy increased in later registry phases. Most patients (60.1%) were receiving comedication at baseline. The most prescribed comedications were drugs used to treat opioid dependence which increased from 9.2% in phase 1 to 24.0% in phase 7. The patients\u2019 mean age decreased from 52.3\u00a0years in phase 1 to 48.7\u00a0years in phase 7. From 2014 to 2019, the proportion of at\u2010risk patients enrolling in the registry increased. To eliminate viral hepatitis as a major public health threat, a continued commitment to engaging underserved populations into the HCV care cascade is needed.<\/jats:p>","DOI":"10.1111\/jvh.13586","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T17:57:21Z","timestamp":1627927041000},"page":"1474-1483","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real\u2010world data from the German Hepatitis C\u2010Registry (DHC\u2010R)"],"prefix":"10.1111","volume":"28","author":[{"given":"Dietrich","family":"H\u00fcppe","sequence":"first","affiliation":[{"name":"Gastroenterologische Gemeinschaftspraxis Herne Herne Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Stoehr","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Interdisziplin\u00e4re Medizin Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Buggisch","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Interdisziplin\u00e4re Medizin Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Mauss","sequence":"additional","affiliation":[{"name":"Centre for HIV and Hepatogastroenterology Duesseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[{"name":"Medizinische Klinik II Universit\u00e4tsklinikum W\u00fcrzburg W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlinde","family":"Teuber","sequence":"additional","affiliation":[{"name":"Practice PD Dr. med. G. Teuber Frankfurt am Main Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Hidde","sequence":"additional","affiliation":[{"name":"AbbVie Germany GmbH &amp; Co. KG Wiesbaden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Lohmann","sequence":"additional","affiliation":[{"name":"AbbVie Germany GmbH &amp; Co. KG Wiesbaden Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bondin","sequence":"additional","affiliation":[{"name":"AbbVie Inc North Chicago Illinois USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Leberstiftungs\u2010GmbH Deutschland Hannover Germany"},{"name":"Klinik f\u00fcr Gastroenterologie Hepatologie und Endokrinologie Medizinische Hochschule Hannover Hannover Germany"},{"name":"Klinik f\u00fcr Gastroenterologie und Hepatologie Universit\u00e4tsklinikum Essen Universit\u00e4t Duisburg\u2010Essen Essen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"World Health Organization (WHO).Global Hepatitis Report 2017.2017. Availableat:https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/255016\/9789241565455\u2010eng.pdf;jsessionid=525893E0A2C6FEDEE194AAEBC45058A6?sequence=1Accessed September 2020."},{"key":"e_1_2_12_3_1","unstructured":"Polaris Observatory.Germany HCV infections.2020. Available at:https:\/\/cdafound.org\/dashboard\/polaris\/dashboard.htmlAccessed September 2020."},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30270-X"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.024"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103-013-1673-x"},{"key":"e_1_2_12_7_1","unstructured":"Robert Koch\u2010Institut (RKI).Epidemiologisches Bulletin.2020;Nr.30\/31."},{"key":"e_1_2_12_8_1","unstructured":"World Health Organization (WHO).Global health sector strategy on viral hepatitis 2016\u20102021.2016. Available at:https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO\u2010HIV\u20102016.06\u2010eng.pdf;jsessionid=B789DC827B02AF7A18F792AB221CF0D5?sequence=1Accessed September 2020."},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2055-6640(20)30329-0"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(20)31138-7"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14324"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30238-7"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12972"},{"key":"e_1_2_12_14_1","unstructured":"World Health Organization (WHO).Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection.2018. Available at:https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273174\/9789241550345\u2010eng.pdf?ua=1Accessed September 2020. 2018."},{"key":"e_1_2_12_15_1","unstructured":"AbbVie Inc.MAVIRET prescribing information. May 2020."},{"key":"e_1_2_12_16_1","unstructured":"Gilead Sciences Inc.VOSEVI prescribing information. November 2019."},{"key":"e_1_2_12_17_1","unstructured":"Merck Sharpe & Dohme Corp.ZEPATIER prescribing information. December 2019."},{"key":"e_1_2_12_18_1","unstructured":"Gilead Sciences Inc.EPCLUSA prescribing information. March 2020."},{"key":"e_1_2_12_19_1","unstructured":"AbbVie Inc.VIEKIRA PAK prescribing information. December 2019."},{"key":"e_1_2_12_20_1","unstructured":"Gilead Sciences Inc.HARVONI prescribing information. March 2020."},{"issue":"1","key":"e_1_2_12_21_1","first-page":"27","article-title":"4 years of direct\u2010acting antivirals (DAAs) in the German Hepatitis C\u2010Registry (DHC\u2010R)","volume":"57","author":"Huppe D","year":"2019","journal-title":"Z Gastroenterol"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14128"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/1178221819835847"},{"key":"e_1_2_12_24_1","unstructured":"BremerV CaiW GassowskiM et al.Drogen und chronische infektionskrankheiten in Deutschland\u2010DRUCK\u2010studie. Robert Koch Institute.2016."},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12875"},{"issue":"7","key":"e_1_2_12_26_1","first-page":"319","article-title":"Changing demographics among populations prescribed HCV treatment, 2013\u20132017","volume":"25","author":"Tsai N","year":"2019","journal-title":"Am J Manag Care"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029066"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0721-1"},{"issue":"2","key":"e_1_2_12_29_1","first-page":"163","article-title":"Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon\u2010free therapy for hepatitis C virus infection","volume":"130","author":"Flisiak R","year":"2020","journal-title":"Pol Arch Intern Med"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00424"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30375-3"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-019-0528-6"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12770"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.epidem.2019.02.003"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-10-7"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.08.018"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.07.015"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz546"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.012"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-019-0338-y"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13925"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13586","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13586","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13586","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T17:46:17Z","timestamp":1693331177000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/jvh.13586"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13586","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"2021-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-24","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}